AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27601554 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1775 in combination with gemcitabine (1,000 mg/m2)
Number of subjects: 0
Study 27601554 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1775 in combination with cisplatin or carboplatin
Number of subjects: 0
Study 27602207 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers screening for malnutrition by MUAC
Number of subjects: 12929
Study 27602207 — intervention group
Group type: COMPARATOR
Intervention: Community health workers screening for malnutrition by MUAC
Number of subjects: 12929
Study 27602228 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE)
Number of subjects: 34
Study 27602228 — intervention group
Group type: COMPARATOR
Intervention: Pool Exercise (PE)
Number of subjects: 34
Study 27602311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (20 million cells implanted once into the nonunion site using a fluoroscopic guide) in combination with platelet lysate (PL) product
Number of subjects: 7
Study 27602761 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA profiling
Number of subjects: 18
Study 27602761 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA assay results
Number of subjects: 18
Study 27602761 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA criteria
Number of subjects: 18
Study 27602967 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/ml hyaluronic acid filler (Juvéderm Voluma® XC)
Number of subjects: 20
Study 27602967 — intervention group
Group type: EXPERIMENTAL
Intervention: Future recommendations for outcome measures
Number of subjects: 20
Study 27603290 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined delivery of antiretroviral therapy (ART) regardless of CD4 cell count, following community-wide HIV-testing.
Number of subjects: 5683
Study 27603290 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined delivery of ART for patients newly linking to care.
Number of subjects: 5683
Study 27603290 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined delivery of ART for patients previously in care.
Number of subjects: 5683
Study 27603290 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined delivery of ART with valid viral load results.
Number of subjects: 5683
Study 27604186 — intervention group
Group type: COMPARATOR
Intervention: High dose sunitinib (20 μM for 6-9 h in vitro; once-weekly in vivo)
Number of subjects: 0
Study 27604186 — intervention group
Group type: COMPARATOR
Intervention: Standard daily sunitinib (50 mg daily, four weeks on, two weeks off)
Number of subjects: 0
Study 27604397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepsin in saliva from patients undergoing 24-hour MII/pH monitoring
Number of subjects: 90
Study 27604397 — intervention group
Group type: COMPARATOR
Intervention: Pepsin in saliva from asymptomatic controls
Number of subjects: 90
Study 27604397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepsin concentration in saliva samples collected within 2 hours after reflux event
Number of subjects: 90
Study 27604397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepsin concentration in saliva samples collected more than 2 hours after reflux event
Number of subjects: 90
Study 27604543 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted social network motivational interviewing intervention
Number of subjects: 11
Study 27604771 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean pork ingestion
Number of subjects: 10
Study 27604773 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread (GI value determined by standardized methodology)
Number of subjects: 63
Study 27604773 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin index and glycated hemoglobin values
Number of subjects: 63
Study 27604981 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide treatment
Number of subjects: 50
Study 27605156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and thalidomide therapy
Number of subjects: 172
Study 27605368 — intervention group
Group type: COMPARATOR
Intervention: ICG-qualitative TSH test kit
Number of subjects: 283
Study 27605368 — intervention group
Group type: COMPARATOR
Intervention: ICG-quantitative TSH analysis system
Number of subjects: 283
Study 27605368 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation serum TSH assay
Number of subjects: 283
Study 27605539 — intervention group
Group type: EXPERIMENTAL
Intervention: DCV+SOF
Number of subjects: 485
Study 27605539 — intervention group
Group type: COMPARATOR
Intervention: DCV+SOF+RBV
Number of subjects: 485
Study 27606973 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) treatment
Number of subjects: 303
Study 27606973 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept monotherapy
Number of subjects: 303
Study 27607476 — intervention group
Group type: COMPARATOR
Intervention: Short-acting opioids (fentanyl)
Number of subjects: 191
Study 27607476 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting opioids (morphine and/or hydromorphone)
Number of subjects: 191
Study 27607476 — intervention group
Group type: COMPARATOR
Intervention: Comparison of long-acting vs short-acting opioids
Number of subjects: 191
Study 27608764 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use disorder
Number of subjects: 1388
Study 27608764 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 1388
Study 27608764 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alcohol use disorder)
Number of subjects: 1388
Study 27609188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 6 ml/kg
Number of subjects: 69
Study 27609188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 8 ml/kg
Number of subjects: 69
Study 27609188 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 10 ml/kg
Number of subjects: 69
Study 27609252 — intervention group
Group type: EXPERIMENTAL
Intervention: +CTO
Number of subjects: 675
Study 27609252 — intervention group
Group type: COMPARATOR
Intervention: -CTO
Number of subjects: 675
Study 27609256 — intervention group
Group type: EXPERIMENTAL
Intervention: Transaortic access for TAVR
Number of subjects: 301
Study 27609682 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation devices (Sapien 3 and Lotus)
Number of subjects: 301
Study 27609682 — intervention group
Group type: COMPARATOR
Intervention: Early-generation devices (Sapien XT and CoreValve)
Number of subjects: 301
Study 27609682 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation devices
Number of subjects: 301
Study 27609682 — intervention group
Group type: COMPARATOR
Intervention: Early-generation devices
Number of subjects: 301
Study 27609689 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators for primary prevention
Number of subjects: 0
Study 27609778 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-oral endoscopic myotomy (POEM)
Number of subjects: 241
Study 27609817 — intervention group
Group type: EXPERIMENTAL
Intervention: (13)N-ammonia positron emission tomography (13NH3-PET)
Number of subjects: 130
Study 27611192 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol enriched margarine (3 g/d plant stanols)
Number of subjects: 42
Study 27611192 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol enriched margarine (3 g/d plant sterols)
Number of subjects: 42
Study 27611192 — intervention group
Group type: COMPARATOR
Intervention: Control margarine (no addition)
Number of subjects: 42
Study 27611967 — intervention group
Group type: EXPERIMENTAL
Intervention: Panchakarma-based Ayurvedic intervention
Number of subjects: 65
Study 27611967 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 27612149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate 0.05% gel
Number of subjects: 26
Study 27612457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean 6-item score according to Giangreco
Number of subjects: 75
Study 27612457 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological findings
Number of subjects: 75
Study 27612457 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizures
Number of subjects: 75
Study 27612457 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorders
Number of subjects: 75
Study 27612457 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 75
Study 27612457 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD/ADD
Number of subjects: 75
Study 27612457 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairment of social behavior
Number of subjects: 75
Study 27612457 — intervention group
Group type: EXPERIMENTAL
Intervention: Other comorbidities
Number of subjects: 75
Study 27612457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Aberrant Behaviour Checklist Community Edition (ABC-C) score
Number of subjects: 75
Study 27612457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean visual analogue scale (VAS) score
Number of subjects: 75
Study 27612488 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE) with 0.4% indigo carmine
Number of subjects: 350
Study 27612488 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (CE)
Number of subjects: 350
Study 27612875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Score (MDS)
Number of subjects: 161
Study 27612875 — intervention group
Group type: EXPERIMENTAL
Intervention: Baltic Sea Diet Score (BSDS)
Number of subjects: 161
Study 27612875 — intervention group
Group type: EXPERIMENTAL
Intervention: Finnish Children Healthy Eating Index (FCHEI)
Number of subjects: 161
Study 27612875 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest third of BSDS and FCHEI
Number of subjects: 161
Study 27612875 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet scores (MDS, BSDS, FCHEI)
Number of subjects: 161
Study 27612924 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-oral endoscopic tunneling for restoration of the esophagus (POETRE)
Number of subjects: 4
Study 27612987 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan followed by autologous hematopoietic stem cell transplantation
Number of subjects: 56
Study 27612987 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy (bortezomib-based in combination with dexamethasone and either thalidomide, cyclophosphamide or lenalidomide) for 4-6 cycles
Number of subjects: 56
Study 27612987 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells collected after high-dose cyclophosphamide plus G-CSF or G-CSF alone
Number of subjects: 56
Study 27612987 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan at 140 mg/m² as conditioning regimen
Number of subjects: 56
Study 27613072 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV) lot released between August 1 and September 15, 2013
Number of subjects: 0
Study 27613072 — intervention group
Group type: COMPARATOR
Intervention: Live attenuated influenza vaccine (LAIV) lot shipped earlier or later than August 1 to September 15, 2013
Number of subjects: 0
Study 27613072 — intervention group
Group type: COMPARATOR
Intervention: LAIV (trivalent or quadrivalent formulations)
Number of subjects: 0
Study 27613072 — intervention group
Group type: EXPERIMENTAL
Intervention: LAIV against A/H3N2 and B strains
Number of subjects: 0
Study 27613189 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DEP regimen (PEG-aspargase and modified DEP regimen)
Number of subjects: 28
Study 27614001 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of pacemaker or defibrillator
Number of subjects: 73
Study 27614001 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at diagnosis < 46 years
Number of subjects: 73
Study 27614001 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate treatment
Number of subjects: 73
Study 27614001 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF > 40%
Number of subjects: 73
Study 27614001 — intervention group
Group type: COMPARATOR
Intervention: Age ≥ 46 years
Number of subjects: 73
Study 27614001 — intervention group
Group type: COMPARATOR
Intervention: Lack of implanted pacemaker or defibrillator
Number of subjects: 73
Study 27614001 — intervention group
Group type: COMPARATOR
Intervention: Reduced LVEF < 40%
Number of subjects: 73
Study 27614001 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 73
Study 27614001 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant or death from sarcoidosis
Number of subjects: 73
Study 27614379 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards Sapien 3 valve (ES3)
Number of subjects: 200
Study 27614912 — intervention group
Group type: EXPERIMENTAL
Intervention: [(14)C]prucalopride succinate 2 mg (~200 nCi)
Number of subjects: 6
Study 27616471 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 0
Study 27616471 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7+DTaP (concomitant)
Number of subjects: 0
Study 27616471 — intervention group
Group type: COMPARATOR
Intervention: DTaP alone
Number of subjects: 0
Study 27616553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg once daily; 28-day cycle)
Number of subjects: 16
Study 27617031 — intervention group
Group type: EXPERIMENTAL
Intervention: Children from low-income families
Number of subjects: 42
Study 27617031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary lifestyle and unhealthy eating habits
Number of subjects: 42
Study 27617031 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals' interventions
Number of subjects: 42
Study 27617496 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-based therapy
Number of subjects: 10
Study 27617637 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training (TCT) of the auditory system, 40 hours duration.
Number of subjects: 131
Study 27618501 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily degludec
Number of subjects: 29
Study 27618681 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective criteria for identifying patients with OHCA with no chance of survival (not witnessed by emergency medical services, nonshockable initial cardiac rhythm, no return of spontaneous circulation before a third 1-mg dose of epinephrine)
Number of subjects: 6963
Study 27618681 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective criteria for identifying patients with OHCA with no chance of survival
Number of subjects: 6963
Study 27619225 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 trabecular micro-bypass stents
Number of subjects: 101
Study 27619225 — intervention group
Group type: COMPARATOR
Intervention: Topical travoprost
Number of subjects: 101
Study 27619774 — intervention group
Group type: EXPERIMENTAL
Intervention: Eeva Test plus standard morphology
Number of subjects: 280
Study 27619774 — intervention group
Group type: COMPARATOR
Intervention: Propensity matched control group (morphology only)
Number of subjects: 280
Study 27619774 — intervention group
Group type: EXPERIMENTAL
Intervention: Eeva High and Medium embryos
Number of subjects: 280
Study 27619774 — intervention group
Group type: EXPERIMENTAL
Intervention: Eeva Low embryos
Number of subjects: 280
Study 27619774 — intervention group
Group type: EXPERIMENTAL
Intervention: Eeva Test group
Number of subjects: 280
Study 27619774 — intervention group
Group type: COMPARATOR
Intervention: Propensity matched control group
Number of subjects: 280
Study 27619954 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea treatment
Number of subjects: 43
Study 27621400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg/d continuously until disease progression or unacceptable toxicity
Number of subjects: 26
Study 27621408 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin plus Palifosfamide
Number of subjects: 0
Study 27621408 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin plus Placebo
Number of subjects: 0
Study 27621833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low eosinophil counts (<0.05 compared with 0.15-0.25×10(9)/L)
Number of subjects: 775231
Study 27621833 — intervention group
Group type: EXPERIMENTAL
Intervention: Low lymphocyte counts (<1.45 vs 1.85-2.15×10(9)/L)
Number of subjects: 775231
Study 27622077 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI9447
Number of subjects: 0
Study 27622077 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MEDI9447 and anti-PD-1 antibodies
Number of subjects: 0
Study 27622157 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT 35 Gy
Number of subjects: 114
Study 27622157 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT 40 Gy
Number of subjects: 114
Study 27622162 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus-positive children
Number of subjects: 624
Study 27622162 — intervention group
Group type: COMPARATOR
Intervention: Rotavirus-negative children
Number of subjects: 624
Study 27622162 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall RVGE cases
Number of subjects: 624
Study 27622162 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization of AGE cases
Number of subjects: 624
Study 27622858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) for 12 weeks
Number of subjects: 768
Study 27622858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) for 24 weeks
Number of subjects: 768
Study 27622858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) + Ribavirin (1-1.2g/day) for 24 weeks
Number of subjects: 768
Study 27622858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) + Ribavirin (1-1.2g/day) for 12 weeks
Number of subjects: 768
Study 27622858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) in non-cirrhotic patients
Number of subjects: 768
Study 27622858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) in cirrhotic patients for 12 weeks
Number of subjects: 768
Study 27622858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (400mg/day) + Daclatasvir (60mg/day) in cirrhotic patients for 24 weeks
Number of subjects: 768
Study 27623532 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented training with interactive computer games and objects of daily life
Number of subjects: 30
Study 27623532 — intervention group
Group type: COMPARATOR
Intervention: Finger mobility and strengthening exercises
Number of subjects: 30
Study 27624138 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated albumin
Number of subjects: 236
Study 27624138 — intervention group
Group type: COMPARATOR
Intervention: Hemoglobin A1c
Number of subjects: 236
Study 27624355 — intervention group
Group type: EXPERIMENTAL
Intervention: No PPM group
Number of subjects: 183
Study 27624355 — intervention group
Group type: COMPARATOR
Intervention: PPM group
Number of subjects: 183
Study 27624417 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious depression group
Number of subjects: 28
Study 27624417 — intervention group
Group type: COMPARATOR
Intervention: Nonanxious depression group
Number of subjects: 28
Study 27624549 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine at 20 mg/m²
Number of subjects: 0
Study 27624571 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-producing Escherichia coli (ESBL-EC)
Number of subjects: 919
Study 27624571 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL-producing Klebsiella pneumoniae (ESBL-KP)
Number of subjects: 919
Study 27624571 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare-associated infections, obstructive urinary tract disease, previous surgical history, and use of a cephalosporin antibiotic within 3 months
Number of subjects: 919
Study 27624571 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 919
Study 27624571 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 919
Study 27624579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic clamp (225 and 400 mg/dl) followed by IV arginine bolus
Number of subjects: 40
Study 27624579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting IAPP concentrations
Number of subjects: 40
Study 27624579 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal IAPP secretion
Number of subjects: 40
Study 27624579 — intervention group
Group type: EXPERIMENTAL
Intervention: IAPP/C-peptide ratio
Number of subjects: 40
Study 27624592 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic function grade (DFG) assessment
Number of subjects: 546
Study 27624592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular morphology
Number of subjects: 546
Study 27624592 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal effort on exercise testing
Number of subjects: 546
Study 27624746 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed Parameter (DP) modeling
Number of subjects: 24
Study 27624746 — intervention group
Group type: COMPARATOR
Intervention: Fermi modeling
Number of subjects: 24
Study 27624746 — intervention group
Group type: COMPARATOR
Intervention: Visual assessments
Number of subjects: 24
Study 27624877 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized visualization of cardiovascular risk levels through a website and group consultation with a nurse
Number of subjects: 600
Study 27625344 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q4W
Number of subjects: 233
Study 27625344 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W
Number of subjects: 233
Study 27625344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 27625358 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA allele-matched unrelated donor transplant with conditioning regimen including alemtuzumab, fludarabine, and melphalan; GVHD prophylaxis with calcineurin inhibitor, short-course methotrexate, and methylprednisolone.
Number of subjects: 30
Study 27625358 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA allele-matched unrelated donor transplant
Number of subjects: 30
Study 27627050 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (150 mg for mild impairment, 100 mg for moderate impairment, escalating to 200 mg)
Number of subjects: 30
Study 27627050 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 30
Study 27627808 — intervention group
Group type: EXPERIMENTAL
Intervention: ARQ 087
Number of subjects: 0
Study 27627818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 120